## Records ?

## **Pediatric Pancreas Transplant Recipient Follow-Up Worksheet**

The revised worksheet sample is for reference purposes only and is pending OMB approval.

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI<sup>B.</sup> application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI<sup>B.</sup> application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Decinions Information	
Recipient Information	
Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
Previous Follow-Up:	Previous Px Stat Date:
Transplant Discharge Date:	
State of Permanent Residence: *	
State of Fermanent Residence. "	
Zip Code: *	
Provider Information	
Recipient Center:	
Followup Center:	
Tollowap Collection	
Physician Name: *	
NPI: *	
	Transplant Center
	Non Transplant Center Specialty Physician
Follow-up Care Provided By: *	C Britanna Cons Blancisian
	Primary Care Physician
	Other Specify
Specify:	
Donor Information	
UNOS Donor ID #:	
Donor Type:	
Patient Status	
Date: Last Seen, Retransplanted or Death ★	
	LIVING
	LIVING
Patient Status: *	• DEAD
	RETRANSPEANTED
Primary Cause of Death:	
Specify:	
opcony.	
Contributory Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Hospitalizations	
Hospitalizations:	
Has the patient been hospitalized since the last patient status date: *	C YES O NO UNK
Number of Hospitalizations:	St=
Noncompliance:	
Was there evidence of noncompliance with immunosuppression medication during this follow-up period that compromised the patient's	C VEO C NO C UNIX
recovery:	YES NO UNK
Functional Status: *	
	<ul> <li>Definite Cognitive delay/impairment (verified by IQ score &lt;70 or unambiguous behavioral observation)</li> </ul>
Cognitive Development: ★	Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on
	behavioral observation or other evidence)

	Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties)						
	No Cognitive delay/impairment (no obvious indicators of cognitive delay/impairment)						
	Not Assessed						
	<ul> <li>Definite Motor delay/impairment (verified by physical exam or unambiguous behavioral observation)</li> </ul>						
	<ul> <li>Probable Motor delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence)</li> </ul>						
Motor Development: ★	<ul> <li>Questionable Motor delay/impairment (not judged to be more likely than not, but with some indications of motor delay/impairment)</li> </ul>						
	No Motor delay/impairment (no obvious indicators of motor delay/impairment)						
	Not Assessed						
	Within One Grade Level of Peers						
	Delayed Grade Level						
Academic Progress: *	Special Education						
	Not Applicable < 5 years old						
	C Status Unknown						
	Full academic load						
	Reduced academic load						
Academic Activity Level: *	Unable to participate in academics due to disease or condition						
, , , , , , , , , , , , , , , , , , , ,	Not Applicable < 5 years old/ High School graduate						
	Status Unknown						
Primary Insurance at Follow-up: *							
Specify:							
Clinical Information							
Clinical Information  Date of Measurement: *							
	ft in cm %ile St=						
Date of Measurement: * Height: * Weight: *	lbs. kg %ile St=						
Date of Measurement: * Height: *							
Date of Measurement: * Height: * Weight: *	lbs. kg %ile St=						
Date of Measurement: *  Height: *  Weight: *  BMI:	kg/m² kg %ile St= St= Functioning Partial Function Failed						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *	kg/m² kg %ile St= St= Functioning Partial Function Failed						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the state of	kg %ile  kg/m² %ile  Functioning Partial Function Failed  Stemps of the factor unrelated to graft failure, select Functioning.						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *	lbs.   kg %ile   St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the state of	lbs.   kg %ile   St=     kg/m²   %ile     St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the state of	lbs.   kg %ile   St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the measurement of the state of the sta	lbs.   kg %ile   St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the measurement of the state of the sta	lbs.   kg %ile   St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the measurement o	lbs.   kg %ile   St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the measurement o	lbs.   kg %ile   St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the insulin/medication resumed:  Date insulin/medication resumed:  Date of Failure:  Pancreas Graft Removed:  Date Pancreas Removed:  Primary Cause of Graft Failure:  Other, Specify:	lbs.   kg %ile   St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the sound of blood sugar control:  Date insulin/medication resumed:  Date of Failure:  Pancreas Graft Removed:  Date Pancreas Removed:  Primary Cause of Graft Failure:  Other, Specify:  Contributory causes of graft failure:	lbs.   kg %ile   St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the insulin/medication resumed:  Date insulin/medication resumed:  Date of Failure:  Pancreas Graft Removed:  Date Pancreas Removed:  Primary Cause of Graft Failure:  Other, Specify:	lbs.   kg %ile   St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the sound of blood sugar control:  Date insulin/medication resumed:  Date of Failure:  Pancreas Graft Removed:  Date Pancreas Removed:  Primary Cause of Graft Failure:  Other, Specify:  Contributory causes of graft failure:	lbs.   kg %ile   St=						
Date of Measurement: *  Height: *  Weight: *  BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the model of the sugar control:  Date insulin/medication resumed:  Date of Failure:  Pancreas Graft Removed:  Date Pancreas Removed:  Primary Cause of Graft Failure:  Other, Specify:  Contributory causes of graft failure:  Graft/Vascular Thrombosis:	lbs.   kg %ile   St=						
Date of Measurement: * Height: * Weight: * BMI:  Graft Status: *  If death is indicated for the recipient, and the death was a result of some of the measurement of the second of the se	lbs.   kg %ile   St=						

Chronic Rejection:	C YES O NO UNK
Biopsy Proven Isletitis:	C YES O NO UNK
Pancreatitis:	C YES ONO UNK
Patient Noncompliance	C YES O NO O UNK
Other, Specify:	
Conv. From Bladder to Enteric Drain Performed: *	C YES ONO UNK
If Yes, Enteric Drainage Date:	
Serum Amylase:	u/L St=
Pancreas Transplant Complications (Not leading to graft failure):	
Pancreatitis: *	C YES ONO UNK
Anastomotic Leak: ★	C YES ONO UNK
Abcess or Local Infection: *	C YES ONO UNK
Other Complications:	
	Yes, at least one episode treated with anti-rejection agent
Did patient have any acute rejection episodes during the follow-up period: *	Yes, none treated with additional anti-rejection agent
	○ No ○ Unknown
	Biopsy not done
Was biopsy done to confirm acute rejection:	<ul><li>Yes, rejection confirmed</li><li>Yes, rejection not confirmed</li></ul>
	Unknown
Postransplant Malignancy: *	C YES ONO UNK
Donor Related:	C YES C NO C UNK
Recurrence of Pre-Tx Tumor:	C YES C NO C UNK
De Novo Solid Tumor:	C YES C NO C UNK
De Novo Lymphoproliferative disease and Lymphoma:	C YES O NO UNK
Treatment	
Biological or Anti-viral therapy:	C YES NO Unknown/Cannot disclose
	Acyclovir (Zovirax)
	Cytogam (CMV)
	Gamimune
	Gammagard
	Ganciclovir (Cytovene)
If Yes, check all that apply:	□ Valgancyclovir (Valcyte) □ HBIG (Hepatitis B Immune Globulin)
	Flu Vaccine (Influenza Virus)
	Lamivudine (Epivir) (for treatment of Hepatitis B)
	Valacyclovir (Valtrex)
	☐ Other, Specify
Specify:	
Specify:	

Other therapies:		YES	S C NO			
	_					
			otopheresis			
If Yes, check all that apply:			smapheresis			
		Tota	al Lymphoid Irradiation (TLI)			
Immunosuppressive Information						
Previous Validated Maintenance Follow-Up Medications:						
		Vac	come on province validated report			
Were any medications given during the follow-up period for maintenance:			, same as previous validated report , but different than previous validated	roport		
			ne given	тероп		
		14011	e giveii			
Did the physician discontinue all maintenance immunosuppressive medications:	0	YES	S C NO			
Did the patient participate in any clinical research protocol for		YES	s C NO			
immunosuppressive medications:  Specify:						
ороопу.						
Immunosuppressive Medications View Immunosuppressive Medications						
Definitions Of Immunosuppressive Follow-Up Medications						
For each of the immunosuppressant medications listed, check <b>Previous Maintena</b> prescribed for the recipient during this follow-up period, and for what reason. If a magnetic previous <b>Maintenance</b> ( <b>Prev Maint</b> ) includes all immunosuppressive medications periods of time which may be either long-term or intermediate term with a tapering Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Recommendate term with a tapering of the dosage until the drug is either eliminated of Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medicated Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from the listed under AR immunosuppression, but should be listed under maintenance. <b>Note: The Anti-rejection field refers to any anti-rejection medications since the maintenance of the medication in the space provided. <b>I</b></b>	s give of the apamy given or repove me ions com Toe impere las (e.g.,	n duri e dosa (cin). at the laced dicati given f acroli munos at clin	was not given, leave the associated box( ing the report period, which covers the p age until the drug is either eliminated or This does not include any immunosupple e current clinic visit to begin in the next re by another long-term maintenance drug ions given to treat rejection episodes. for the purpose of treating an acute rejectimus to Cyclosporine; or from Mycopher suppression. nic visit, not just at the time of the cur monoclonal antibodies), select Previous	es) blank.  eriod from the last clin replaced by another lo essive medications give eport for varying perio (example: Prednisone ction episode since the olate Mofetil to Azathi rent clinic visit.  Maint, or Current Main	ic visit to the current clang-term maintenance when to treat rejection exists of time which may be Cyclosporine, Tacrolical last clinic visit (example poprine) because of rejections.	inic visit, for varying drug (example: bisodes. e either long-term or mus, Mycophenolate ble: Methylprednisolone, ection, the drugs should
Steroids (Prednisone, Methylprednisolone, Solumedrol, Medrol, Decadron)				Prev Maint	Curr Maint	AR
Atgam (ATG)						
OKT3 (Orthoclone, Muromonab)						
Thymoglobulin						
Simulect - Basiliximab						
Zenapax - Daclizumab						
Azathioprine (AZA, Imuran)						
EON (Generic Cyclosporine)				_		
Gengraf (Abbott Cyclosporine)						
Gengraf (Abbott Cyclosporine)  Other generic Cyclosporine, specify brand:						
Other generic Cyclosporine, specify brand:						
Other generic Cyclosporine, specify brand:  Neoral (CyA-NOF)						
Other generic Cyclosporine, specify brand:  Neoral (CyA-NOF)  Sandimmune (Cyclosporine A)						
Other generic Cyclosporine, specify brand:  Neoral (CyA-NOF)  Sandimmune (Cyclosporine A)  Mycophenolate Mofetil (MMF, Cellcept, RS61443)						
Other generic Cyclosporine, specify brand:  Neoral (CyA-NOF)  Sandimmune (Cyclosporine A)  Mycophenolate Mofetil (MMF, Cellcept, RS61443)  Tacrolimus (Prograf, FK506)						
Other generic Cyclosporine, specify brand:  Neoral (CyA-NOF)  Sandimmune (Cyclosporine A)  Mycophenolate Mofetil (MMF, Cellcept, RS61443)  Tacrolimus (Prograf, FK506)  Modified Release Tacrolimus FK506E (MR4)						
Other generic Cyclosporine, specify brand:  Neoral (CyA-NOF)  Sandimmune (Cyclosporine A)  Mycophenolate Mofetil (MMF, Cellcept, RS61443)  Tacrolimus (Prograf, FK506)  Modified Release Tacrolimus FK506E (MR4)  Sirolimus (RAPA, Rapamycin, Rapamune)  Myfortic (Mycophenolate Sodium)						
Other generic Cyclosporine, specify brand:  Neoral (CyA-NOF)  Sandimmune (Cyclosporine A)  Mycophenolate Mofetil (MMF, Cellcept, RS61443)  Tacrolimus (Prograf, FK506)  Modified Release Tacrolimus FK506E (MR4)  Sirolimus (RAPA, Rapamycin, Rapamune)					Curr Maint	
Other generic Cyclosporine, specify brand:  Neoral (CyA-NOF)  Sandimmune (Cyclosporine A)  Mycophenolate Mofetil (MMF, Cellcept, RS61443)  Tacrolimus (Prograf, FK506)  Modified Release Tacrolimus FK506E (MR4)  Sirolimus (RAPA, Rapamycin, Rapamune)  Myfortic (Mycophenolate Sodium)						
Other generic Cyclosporine, specify brand:  Neoral (CyA-NOF)  Sandimmune (Cyclosporine A)  Mycophenolate Mofetil (MMF, Cellcept, RS61443)  Tacrolimus (Prograf, FK506)  Modified Release Tacrolimus FK506E (MR4)  Sirolimus (RAPA, Rapamycin, Rapamune)  Myfortic (Mycophenolate Sodium)  Other Immunosuppressive Medications  Campath - Alemtuzumab (anti-CD52)  Cyclophosphamide (Cytoxan)				Prev Maint	Curr Maint	
Other generic Cyclosporine, specify brand:  Neoral (CyA-NOF)  Sandimmune (Cyclosporine A)  Mycophenolate Mofetil (MMF, Cellcept, RS61443)  Tacrolimus (Prograf, FK506)  Modified Release Tacrolimus FK506E (MR4)  Sirolimus (RAPA, Rapamycin, Rapamune)  Myfortic (Mycophenolate Sodium)  Other Immunosuppressive Medications  Campath - Alemtuzumab (anti-CD52)				Prev Maint	Curr Maint	

Other Immunosuppressive Medication, Specify				
Other Immunosuppressive Medication, Specify				
Rituximab				
Investigational Immunosuppressive Medications				
Investigational Immunosuppressive Medications	Prev Maint	Curr Maint	AR	
Investigational Immunosuppressive Medications  Everolimus (RAD, Certican)	Prev Maint	Curr Maint	AR	
	_	_	_	